Abstract��
To investigate the instruction for drug use for pregnant and lactating women and to provide reference for standardizing drug package inserts METHODSFour hundred and ninty drug instructions sampled from the pharmacy in our hospital were investigated and analyzed on the part for pregnant and lactating women medication by Provisions for Drug Insert Sheets and Labels��Regulatory Guidelines for the chemicals non��prescription drug�� Regulatory Guidelines for chemicals and living creature product and other references RESULTSIn prescription medicines�� The rate of pregnant and lactating women to use the medicine circumstance marked was 53.91%�� and that of "not yet clear"or "still have no data”was 13.28%�� and the other 32.81% have never carried on to mark In non��prescription medicines�� The rate of pregnant and lactating women to use the medicine circumstance marked was 46.23%�� 53.77% have never carried on to mark CONCLUSIONThe contents of pregnant and lactating women medication are far from perfect��Which should draw attention to better management.
LI Xin-Lei,
FENG Xin-*
.Analysis of Pregnant and Lactating women Medication in 490 Drug Instructions[J] Chinese Pharmaceutical Journal, 2013,V48(21): 1886-1888
��
[1]
SCHMADER K E. Epidemiology and impact on quality of life ofpostherpetic neuralgia and painful diabetic neuropathy. Clin J Pain,2002,18:350-354.[2] MCKINLAY J,MARCEAU L. US public health and the 21st century:Diabetesmellitus. Lancet,2000,356(9231):757-761.[3] GUO X,LIU X L,CHENG H. Pharmacokinetics of pregabalinsulfate in human. Chin Pharm J(�й�ҩѧ��־),2009,44(5):362-366.[4] LESSER H,SHARMA U,LAMOREAUX L,et al. Pregabalin relieves symptoms of painful diabetic neuropathy:A randomized controlled trial. Neurology,2004,63(11):2104-2110.[5] ROSENSTOCK J,TUCHMAN M,LAMOREAUX L,et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy:A double-blind, placebo-controlled trial. Pain,2004,110(3):628-638.[6] RICHTER R W,PORTENOY R,SHARMA U,et al. Relief of painful diabetic peripheral neuropathy with pregabalin:a randomized,placebo-controlled trial. Pain,2005,6(4):253-260.[7] FREYNHAGEN R,STROJEK K,GRIESING T,et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised,double-blind,multicentre,placebo-controlled trial of flexible -and fixed-dose regimens. Pain,2005,115(3):254-263.[8] AREZZO J C,ROSENSTOCK J,LAMOREAUX L,et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy:A double-blind placebo-controlled trial. BMC Neurol,2008,8:33.[9] THOMAS T, FREYNHAGEN R,VERSAVEL M,et al.Pregabalin for relief of neuropathic pain associated with diabetic neuropathy:A randomized,double-blind study. Eur J Pain,2008,12(2):203-213.[10] BARON R,MAYORAL V,LEIJON G,et al. Efficacy and safety of 5% lidocaine(lignocaine) medicated plaster in comparison with pregabalin in patients with postherpeticneuralgiaand diabetic polyneuropathy:Interim analysis from an open-label,two-stage adaptive,randomized,controlled trial.Clin Drug Invest,2009,29 (4):615-626.[11] TANENBERG R J,IRVING G A, RISSER R C, et al. Duloxetine,pregabalin,and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin:An open-label, randomized,non-inferiority comparison. Mayo Clin Proc,2011,86(7):615-626.[12] SUN D H,JI C M,MA L,et al.Efficacy and safety of pregabalin in patients with diabetic painful neuropathy.Chin J New Drugs(�й���ҩ��־),2011,20(14):1302-1304.[13] MA J M,YA P,LAN P L,et al. Clinical application of oxycodone hydrochloride controlled-release tablets combinedwith pregabalin treatment for painful diabetic neuropathy.Pract Pharm Clin Remedies(ʵ��ҩ�����ٴ�),2012,15(5):262-264.
[2]
XIE Y R��CAI D��YU B R��et al. Primary analysis of some problems in dispensatory and recommendation[J]. Chin Pharm(�й�ҩ����,2008��19(4)��311-312. [2]MIQUEL A V, ORTIN FONT F, MARRUGAT J, et al. Assessment of the comprehension of new rephrasing drug package inserts[J]. Med Clin, 2000, 115(11)��410-417.[3]WATSON K T, BARASH P G. The new Food and Drug Administration drug package insert��implications for patient safety and clinical care[J]. Anesth Analg , 2009, 108(1)��211-218.[4]CHEN H X��DUAN T Drugs in pregnancy and lactation[M]. Beijing�� People��s Medical Publishing House, 2008��29-30.[5]Ministry of public health rational drugs committeeMCDEX(�й�ҽʦҩʦ�ٴ���ҩָ��)[M]. Chongqing�� Chongqing publishing company��2009��677.[6]CHEN X Q��JIN Y Y��TANG G, et al.New pharmaceutics[M]. Beijing��People��s Medical Publishing House, 2007��562.[7] Chinese Pharmacopoeia Commission. Clinical medication notice (�ٴ���ҩ��֪)[M]. Beijing��People��s Medical Publishing House��2005��246-251. [8]ZHU J, CHEN F, CHEN Q H, et al. An important instructions on the poor analysis[J].Chin Pharm(�й�ҩ����,2008��19(6)��477.[9]LIN T��LUO R W��GUO L B.The proprietary chinese patent medicine investigation specification investigation and analysis[J]. Chin Med Guide(�й���ҩָ�ϣ���2010��4(8)��88-89.[10]ZHANG J F, LIU J, CHANG S X��et al . Problems in the drug label instructions[J]. Chin Pharm J(�й�ҩѧ��־����2001��11(36)��74.
2013, Vol. 48 